|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
Trading: BUY @ $46.58
Signal Strength: STRONG
Indicator CAN BE USED in additional to another technical indicator to confirmation for trading position. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This Japanese candlestick indicator can provide guidance on the short term battle between sellers and buyers from the companies recent trading.
Ra Pharmaceuticals Inc (NASDAQ:RARX) has formed a new Bull Belt-Hold reversal pattern.
Bullish Belt Hold is a single candlestick pattern basically a White Opening Marubozu that occurs in a downtrend. It opens on the low of the day and then a rally begins during the day against the overall trend of the market which eventually stops with a close near the high leaving a small shadow on top of the candle. If longer bodies characterize the Belt Hold then the resistance they offer against the trend will be even much stronger.
Calculation: Bull Belt-Hold Candlestick Pattern:
1) The market is characterized by a prevailing downtrend;
2) The market gaps down and opens at its low and closes near to the high of the day;
3) A long white body that has no lower shadow (a White Opening Marubozu) is observed;
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|NVAX Novavax Inc||11.8||28.1||27,140,609||0||NEUTRAL|
|STKL Sunopta Inc||2.69||13||767,118||0||NEUTRAL|
|ECPG Encore Capital||34.61||12||1,185,057||0||NEUTRAL|
|NSTG Nanostring Tech||35.86||11.2||1,613,550||0||NEUTRAL|
|VIVO Meridian Bioscience||8.16||9.2||1,886,706||0||NEUTRAL|
|BCRX BioCryst Pharmaceuticals||2.74||8.3||11,180,169||0||NEUTRAL|
|STAA Staar Surgical||31.05||8||1,662,302||0||NEUTRAL|
|CRIS Curis Inc||1.23||7||256,944||0||NEUTRAL|
|PME Pingtan Marine||1.26||5||12,660||0||NEUTRAL|